Oberweis Asset Management Inc. Invests $4.63 Million in AtriCure, Inc. (NASDAQ:ATRC)

Oberweis Asset Management Inc. bought a new position in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 151,500 shares of the medical device company's stock, valued at approximately $4,630,000. Oberweis Asset Management Inc. owned approximately 0.31% of AtriCure at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Heck Capital Advisors LLC purchased a new stake in shares of AtriCure in the 4th quarter valued at about $60,000. Venturi Wealth Management LLC increased its holdings in shares of AtriCure by 1,337.6% in the 4th quarter. Venturi Wealth Management LLC now owns 2,257 shares of the medical device company's stock worth $69,000 after buying an additional 2,100 shares during the last quarter. KBC Group NV lifted its holdings in shares of AtriCure by 65.3% during the 4th quarter. KBC Group NV now owns 2,360 shares of the medical device company's stock worth $72,000 after acquiring an additional 932 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in AtriCure by 232.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 2,871 shares of the medical device company's stock valued at $88,000 after acquiring an additional 2,008 shares during the last quarter. Finally, R Squared Ltd bought a new position in shares of AtriCure during the 4th quarter valued at about $89,000. 99.11% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ATRC has been the subject of a number of analyst reports. Stifel Nicolaus increased their price objective on AtriCure from $36.00 to $48.00 and gave the company a "buy" rating in a research note on Thursday, February 13th. Oppenheimer raised their price target on shares of AtriCure from $36.00 to $45.00 and gave the stock an "outperform" rating in a report on Thursday, February 13th. Needham & Company LLC reaffirmed a "buy" rating and set a $51.00 price objective on shares of AtriCure in a research note on Thursday, March 27th. BTIG Research reiterated a "buy" rating on shares of AtriCure in a report on Thursday, March 27th. Finally, JPMorgan Chase & Co. reduced their price target on AtriCure from $51.00 to $46.00 and set an "overweight" rating on the stock in a report on Thursday, March 27th. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, AtriCure has an average rating of "Moderate Buy" and a consensus target price of $49.44.

AtriCure Stock Up 0.8 %

ATRC traded up $0.27 during midday trading on Monday, reaching $33.67. The company's stock had a trading volume of 719,038 shares, compared to its average volume of 655,906. The stock's 50-day moving average is $34.32 and its 200-day moving average is $34.66. AtriCure, Inc. has a 1 year low of $18.94 and a 1 year high of $43.11. The firm has a market capitalization of $1.67 billion, a price-to-earnings ratio of -35.44 and a beta of 1.65. The company has a current ratio of 3.65, a quick ratio of 2.62 and a debt-to-equity ratio of 0.13.

Insider Activity at AtriCure

In other news, Director Karen Prange sold 6,100 shares of the firm's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $38.12, for a total transaction of $232,532.00. Following the completion of the transaction, the director now directly owns 17,828 shares in the company, valued at $679,603.36. This trade represents a 25.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 3.50% of the stock is owned by corporate insiders.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.